Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEOGENOMICS INC Director's Dealing 2018

Aug 3, 2018

32227_dirs_2018-08-03_6e1a87e6-7409-452e-a2b7-6d800e2caa21.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2018-08-01

Reporting Person: VAN OORT DOUGLAS M (Director, Chairman and CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2018-08-01 Common Stock A 46429 Acquired 2054552 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 187500 Indirect

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy $7.15 2021-04-20 Common Stock (472527.0) 472527 Direct
Stock Option (Right to Buy) $7.52 2022-04-28 Common Stock (500000.0) 500000 Direct
Stock Option (Right to Buy) $8.03 2023-02-26 Common Stock (500000.0) 500000 Direct

Footnotes

F1: On August 1, 2018, Mr. VanOort was granted 46,429 shares of restricted stock. These shares vest ratably over the first three anniversary dates of the grant date.

F2: Conundrum Capital Partners, LLC is a limited liability partnership 50% owned by Mr. VanOort. Mr.VanOort is a managing partner of Conundrum Capital Partners, LLC.

F3: On April 20, 2016, Mr. VanOort was granted 472,527 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F4: On April 28, 2017, Mr. VanOort was granted 500,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F5: On February 26, 2018, Mr. VanOort was granted 500,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.